What are biosimilars and how do they impact pharmaceutical companies?

Biosimilars are biological products highly similar to an already approved biological medicine. They are not exact generics but aim to provide similar efficacy and safety. For companies like Amgen Inc., biosimilar competition can erode sales of key blockbuster drugs, creating pressure on revenue and market share, necessitating strategic responses such as pipeline diversification and cost management.

What is meant by a "robust oncology portfolio" and why is it important for a biopharma company?

A "robust oncology portfolio" refers to a strong and diverse collection of cancer treatments. For a company like Amgen Inc., this signifies multiple successful drugs, such as Lumakras, addressing various cancer types. It is crucial for sustained revenue growth, establishing a strong market presence, and reducing reliance on any single product, thereby enhancing long-term stability.

How does the Price-to-Earnings (P/E) ratio help assess a company's valuation?

The P/E ratio is a valuation metric comparing a company's share price to its earnings per share. It indicates how much investors are willing to pay for each pound of a company's earnings. A lower P/E, such as Gilead Sciences Inc.'s 14.19, might suggest an attractive valuation, potentially indicating the stock is undervalued compared to its industry peers, assuming consistent earnings.

What are the implications of "biosimilar competition" for investors?

For investors, biosimilar competition typically implies a threat to the market exclusivity and revenue streams of established blockbuster drugs. Companies facing this, such as Amgen Inc. with products like Enbrel and Prolia, may experience reduced sales and profitability, potentially impacting dividend growth and overall financial performance. This often necessitates a focus on innovation and new product development.

How do "high R&D expenses" affect a company's financial health and future prospects?

High Research and Development (R&D) expenses, as seen with Amgen Inc.'s obesity drug progress, can initially weigh on a company's profit margins and earnings. However, these investments are vital for driving future growth by developing new drugs and expanding the product pipeline. Successful R&D can lead to lucrative new revenue streams, market leadership, and long-term shareholder value.

Why would an "attractive valuation" be considered a positive for a stock?

An attractive valuation, like Gilead Sciences Inc.'s forward P/E of 14.19 trading at a discount, suggests that the company's shares may be undervalued relative to its earnings potential or compared to competitors. This could appeal to investors looking for growth opportunities at a reasonable price, as the stock might have significant room for appreciation if its performance improves or market sentiment shifts.

What might "insider sales" indicate to potential investors?

Insider sales refer to company executives or directors selling their own shares. While there can be various personal reasons for such transactions, significant or widespread insider selling, as observed with Gilead Sciences Inc., might signal that those closest to the company perceive limited near-term upside or have concerns about its future performance. Investors often monitor these actions closely.

How do "regulatory delays" affect a biotechnology company's market position?

Regulatory delays, such as those impacting Amgen Inc.'s novel assets like MariTide, can significantly affect a biotechnology company's market position. They delay the launch of potentially lucrative products, postponing revenue generation and allowing competitors to advance. Such delays increase uncertainty, can erode investor confidence, and impact market share, making pipeline execution a critical factor for success.

What is the significance of a "dominant franchise" within a specific disease area like HIV?

A dominant franchise, such as Gilead Sciences Inc.'s strong position in the HIV market with products like Yeztugo and Descovy, provides a stable and predictable revenue stream. This leadership establishes the company as a key player in that therapeutic area, offering a competitive advantage, supporting further investment in related research, and enhancing overall market stability and recognition.

How should a beginner interpret the information provided on this comparison page?

Beginners should interpret this page as an educational tool to understand various financial and market aspects of companies like Amgen Inc. and Gilead Sciences Inc. It offers general insights and context for comparing two biotechnology firms. Please remember, this content is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Always conduct your own comprehensive research before making investment decisions.

Live Report · Updated 26 June 2026

Amgen vs Gilead Sciences

Large biotech company with established medicines and steady dividends vs Pharmaceutical giant with HIV hepatitis and cancer treatments. Which is the better buy for your portfolio in June 2026? Plain-English answer below.

Amgen pioneers biologic therapeutics and biosimilars from a massive internal R&D engine and a late-cycle acquisition strategy anchored by the Horizon Therapeutics deal, while Gilead Sciences dominates HIV and liver disease treatments and has spent years trying to diversify into oncology. Both large-cap biotechs generate prodigious free cash flow and return capital aggressively, yet their pipeline profiles and therapeutic concentrations differ significantly. The Amgen vs Gilead Sciences breakdown shows investors how patent cliff exposure, pipeline depth, and capital allocation choices separate two cash-rich biotech giants navigating the next decade of drug approvals.

Amgen pioneers biologic therapeutics and biosimilars from a massive internal R&D engine and a late-cycle acquisition strategy anchored by the Horizon Therapeutics deal, while Gilead Sciences dominates...

Comparison Snapshot

Key Financial Metrics

AMGN

Metric

GILD

$190.42B

Market Cap

$153.76B

-6.61%

Potential Profit

-0.29%

Hold

Analyst Rating

Buy

Why It’s Moving

Analysts Trim AMGN Outlook as Obesity Drug Hype Meets Reality and New Safety Concerns

Truist analyst Srikripa Devarakonda downgraded AMGN from 'Buy' to 'Hold,' arguing that the market has overestimated the near-term impact of the obesity drug minority and that current valuations reflect excessive optimism.
The FDA issued a caution in late March 2026 about serious liver injury risks, including vanishing bile duct syndrome, associated with Tavneos (avopan), a drug distributed by Amgen, adding a new layer of regulatory uncertainty for investors.
Sector-wide consensus among 30 to 35 analysts has shifted toward a 'Hold' rating as concerns mount over patent expirations, rising competition in the obesity drug market, and near-term revenue pressure despite solid first-quarter results.

Sentiment:

🐻Bearish

Gilead Sciences Faces Fresh Pressure as Major Analysts Downgrade Stock Following Legal Settlement and Bearish Technicals

$202 million legal settlement with U.S. attorneys general has intensified valuation concerns and rattled investor confidence in the drug developer.
Multiple major analysts downgraded the stock or lowered price targets, pointing to bearish technical signals including a MACD divergence and oversold RSI readings.
The stock is trading below critical moving averages with a forward P/E ratio of 13.6, which analysts argue does not meet current quality standards for growth.

Sentiment:

🐻Bearish

Analysts Trim AMGN Outlook as Obesity Drug Hype Meets Reality and New Safety Concerns

Truist analyst Srikripa Devarakonda downgraded AMGN from 'Buy' to 'Hold,' arguing that the market has overestimated the near-term impact of the obesity drug minority and that current valuations reflect excessive optimism.
The FDA issued a caution in late March 2026 about serious liver injury risks, including vanishing bile duct syndrome, associated with Tavneos (avopan), a drug distributed by Amgen, adding a new layer of regulatory uncertainty for investors.
Sector-wide consensus among 30 to 35 analysts has shifted toward a 'Hold' rating as concerns mount over patent expirations, rising competition in the obesity drug market, and near-term revenue pressure despite solid first-quarter results.

Sentiment:

🐻Bearish

Gilead Sciences Faces Fresh Pressure as Major Analysts Downgrade Stock Following Legal Settlement and Bearish Technicals

$202 million legal settlement with U.S. attorneys general has intensified valuation concerns and rattled investor confidence in the drug developer.
Multiple major analysts downgraded the stock or lowered price targets, pointing to bearish technical signals including a MACD divergence and oversold RSI readings.
The stock is trading below critical moving averages with a forward P/E ratio of 13.6, which analysts argue does not meet current quality standards for growth.

Sentiment:

🐻Bearish

Investment Analysis

Amgen

AMGN

Pros

Amgen maintains a robust oncology portfolio with blockbuster drugs like Lumakras driving consistent revenue growth.
Rare disease franchise, including Tepezza, provides high-margin recurring revenues and shields against generic erosion.
Strong balance sheet supports dividend growth and strategic acquisitions amid pipeline advancements.

Considerations

Biosimilar competition erodes sales of key blockbusters such as Enbrel and Prolia.
High R&D expenses pressure margins despite obesity drug progress in early stages.
Regulatory delays in novel assets like MariTide expose pipeline execution risks.

Gilead Sciences

GILD

Pros

Dominant HIV franchise with Yeztugo launch momentum bolsters market share alongside Descovy's 45% penetration.
Attractive valuation at forward P/E of 14.19 trades at discount to industry peers.
Expanding oncology pipeline nears key regulatory milestones for sustained growth.

Considerations

Upcoming quarterly EPS projected to decline 1.58% year-over-year amid flat revenue.
Recent insider sales signal potential short-term concerns over performance.
Modest consensus price target implies limited near-term upside from current levels.

Related Market Insights

Cancer Therapies: What's Next After 100% Response Rate

Regeneron's 100% response rate signals a new era in cancer treatment. Explore investment opportunities in immuno-oncology & breakthrough therapies with Nemo.